We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.
|Bid||1.12 x 3000|
|Ask||1.25 x 200|
|Day's Range||1.12 - 1.19|
|52 Week Range||0.52 - 3.15|
|PE Ratio (TTM)||-1.10|
|Earnings Date||Aug 3, 2017 - Aug 7, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||5.33|
NEW YORK, NY / ACCESSWIRE / September 22, 2017 / U.S. markets retreated from record highs a day after the Federal Reserve announced that it would begin unwinding its $4.5 trillion balance sheet in October ...
REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., Aug. 23, 2017-- Ocera Therapeutics, Inc., today announced that four abstracts related to clinical study findings of OCR-002 in development for the ...
REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2017-- Ocera Therapeutics, Inc., a clinical stage biopharmaceutical company focused on the development of OCR-002 for the treatment and prevention ...
NEW YORK, NY / ACCESSWIRE / May 9, 2017 / Ocera Therapeutics, Inc. (NASDAQ: OCRX ) will be discussing their earnings results in their Q1 Earnings Call to be held May 9, 2017 at 4:30 PM Eastern Time. To ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Ocera Therapeutics, Inc. Here are 5 ETFs with the largest exposure to OCRX-US. Comparing the performance and risk of Ocera Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
|Downgrade||JMP Securities : to Market Perform||1/31/2017|
|Initiated||H.C. Wainwright : to Buy||12/28/2016|
|Initiated||Aegis Capital : to Buy||11/4/2016|
|Initiated||Brean Capital : to Buy||2/23/2016|
|Initiated||JMP Securities : to Market Outperform||6/11/2014|
|+ Upgrade||BMO Capital : to Outperform||1/6/2014|
Industry : Biotechnology
Full Time Employees : 19
Ocera Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the development and commercialization of OCR-002, which is in Phase IIb trials for the treatment of hyperammonemia and hepatic encephalopathy in patients with liver cirrhosis, acute liver injury or failure, and in the areas of unmet medical need. The company is headquartered in Palo Alto, California.